Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: results from the HORIZONS UK national cohort study

Glasspool, R. et al. (2022) Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: results from the HORIZONS UK national cohort study. Gynecologic Oncology, 165(3), pp. 610-618. (doi: 10.1016/j.ygyno.2022.03.012) (PMID:35351333)

Abstract

Objective: Personalised care requires the identification of modifiable risk factors so that interventions can be implemented rapidly following a gynaecological cancer diagnosis. Our objective was to determine what pre-treatment factors are associated with quality of life (QOL) at baseline (pre-treatment) and 12 months. Methods: 1222 women with a confirmed diagnosis of endometrial, ovarian, cervical or vulvar cancer from 82 UK NHS hospitals agreed to complete questionnaires at baseline, three and 12 months. Questionnaires included measures of QOL, health, lifestyle, support and self-management. The primary outcome measure was QOL as measured by Quality of Life in Adult Cancer Survivors (QLACS). Sites provided clinical data at baseline, six and 12 months. Linear regression models were constructed to examine the association between baseline characteristics and QOL outcomes. Results: QOL declined between baseline and 3 months, followed by an improvement at 12 months. Baseline (pre-treatment) factors associated with worse QOL at both baseline and 12 months were depression, anxiety, living in a more deprived area and comorbidities which limit daily activities, whereas higher self-efficacy and age of 50+ years were associated with better QOL. Conclusions: Depression, anxiety and self-efficacy are modifiable risk factors that can impact on QOL. Screening for these, and assessment of whether comorbidities limit daily activities, should be incorporated in a holistic needs assessment and interventions to improve self-efficacy should be made available. Care can then be personalised from the outset to enable all women with a gynaecological cancer the opportunity to have the best QOL.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Glasspool, Dr Rosalind
• Authors: Glasspool, R., Wheelwright, S., Bolton, V., Calman, L., Cummings, A., Elledge, B., Foster, R., Frankland, J., Smith, P., Stannard, S., Turner, J., Wright, D., and Foster, C.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: Gynecologic Oncology
• Publisher: Elsevier
• ISSN: 0090-8258
• ISSN (Online): 1095-6859
• Published Online: 26 March 2022
• Copyright Holders: Copyright © 2022 The Authors
• First Published: First published in Gynecologic Oncology 165(3): 610-618
• Publisher Policy: Reproduced under a Creative Commons License